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LETTER TO THE EDITOR Open Access
Mitochondrial DNA mutations in
Parkinson's disease brain
David K. Simon* , Joanne Clark Matott, Janaina Espinosa and Neeta A. Abraham
Please see the related Research article (10.1186/
s40478-016-0404-6) and the related Letter to
the Editor (10.1186/s40478-017-0434-8)
Dear Editors,
We read with interest the publication by Wei et al.,
Mitochondrial DNA Point Mutations and Relative Copy
Number in 1363 Disease and Control Human Brains,
Acta Neuropathol Commun. 2017; 5: 13 [4]. We disagree
with the authors’ conclusion that their data indicate that,
“single nucleotide variants of mtDNA are unlikely to
play a major role in the pathogenesis of these neurode-
generative disease.” There are 4 specific reasons why we
disagree with this conclusion, and instead we assert that
their data are not contradictory to our own previously
published data indicating significantly elevated levels of
heteroplasmic mtDNA mutations in dopaminergic neu-
rons in the substantia nigra (SN) of Parkinson’s disease
(PD) patients compared to controls at very early patho-
logical stages of PD [2]. 1) Wei et al. looked at cerebellar
tissue for 1189 out of the 1363 cases, and so their data
do not address the levels of mtDNA mutations within a
pathologically affected tissue in PD. In contrast, in our
prior publication we looked specifically at the SN; 2)
Wei et al. looked at brain homogenate rather than specifi-
cally at vulnerable neurons. In contrast, in our prior publi-
cation we looked specifically at dopaminergic neurons
isolated by laser capture microdissection (LCM); 3) Wei
et al. did not discuss the pathological stage of the disease
for the brain tissue that was studied. In most cases, post-
mortem brain tissue available from PD patients is at an
advanced pathological stage at which point most dopa-
minergic SN neurons have died. In contrast, in our prior
publication we analyzed SN neurons from early patho-
logical stages of PD separately from tissue demonstrating
advanced pathological stages. 4) Wei et al. defined mutations
as being homoplasmic if they were present in <10%
or >90% of reads. However, our prior studies found numer-
ous point mutations in mtDNA that were individually rare
(present in <10% of mtDNA copies), but that, in aggregate,
reach a high mutational burden. In agreement with Wei et
al., we previously reported no differences in heteroplasmic
mtDNA point mutations in PD compared to controls when
analyzing late-stage brain homogenate (SN in the case of our
study) [3]. We hypothesized that mutations might preferen-
tially accumulate in neurons rather than other cell types,
which we later confirmed [1], and that those neurons that
accumulate high levels of mutations die, and so are not
present for analysis in end-stage tissue. This led to our subse-
quent study using LCM to analyze heteroplasmic mtDNA
point mutation levels in early-stage dopaminergic SN neu-
rons, which revealed significantly higher levels of mutations
compared to levels in either age-matched controls or in
advanced stage PD SN neurons. Therefore, in contrast to
their conclusion, the data presented in Wei et al. does not
contradict our prior work, and does not provide an argu-
ment against our hypothesis that somatic mtDNA point
mutations accumulate within dopaminergic SN neurons
and contribute to the degenerative process in PD.
Sincerely,
David K. Simon, MD PhD
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